The Journal of Experimental Medicine
Janeway's Immunobiology 7th Edition
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

Published online 25 September 2006 doi:10.1084/jem.20061800
Rockefeller University Press, 0022-1007 $8.00
JEM, Volume 203, Number 10, 2223-2227
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Freeman, G. J.
Right arrow Articles by Sharpe, A. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Freeman, G. J.
Right arrow Articles by Sharpe, A. H.
Related Collections
Right arrowRelated Article
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

COMMENTARY

Reinvigorating exhausted HIV-specific T cells via PD-1–PD-1 ligand blockade

Gordon J. Freeman, E. John Wherry, Rafi Ahmed, and Arlene H. Sharpe

CORRESPONDENCE G.J.F.: gordon_freeman{at}dfci.harvard.edu


ABSTRACT
The programmed death (PD)-1–PD-1 ligand (PD-L) pathway, which is part of the B7–CD28 family, consists of the PD-1 receptor and its two ligands PD-L1 and PD-L2. Engagement of PD-1 by its ligands inhibits immune responses, and recent work has shown that PD-1 is highly expressed on exhausted T cells during chronic lymphocytic choriomeningitis virus (LCMV) infection in mice. Blockade of this pathway reinvigorates the exhausted T cells, allowing them to expand and produce effector cytokines, raising the issue of whether this pathway has been exploited by a variety of viruses during chronic infection. New studies now extend these observations to HIV infection and human disease.


G.J.F. is at Department of Medical Oncology, Dana-Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, MA 02115.

E.J.W. is at Immunology Program, The Wistar Institute, Philadelphia, PA 19104.

R.A. is at Emory Vaccine Center and Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA 30322.

A.H.S. is at Department of Pathology, Harvard Medical School and Brigham and Women's Hospital, Boston, MA 02115.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Related Article

PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection
Constantinos Petrovas, Joseph P. Casazza, Jason M. Brenchley, David A. Price, Emma Gostick, William C. Adams, Melissa L. Precopio, Timothy Schacker, Mario Roederer, Daniel C. Douek, and Richard A. Koup
J. Exp. Med. 2006 203: 2281-2292. [Abstract] [Full Text] [PDF]



This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS